EUVIMEDEUVIMED entdecken
KohortenstudieOpen Access · CC BY 4.0

Clinical Outcomes of Selenium Supplementation in Hashimoto's Thyroiditis Without Selenium Deficiency: A Large‐Scale Retrospective Cohort Study

Eman A Toraih iD, Sarah Yaghi, Claire Ardis, Lori Tran, Ahmed Abdelmaksoud, Rami M Elshazli iD, Mohammad H Hussein iD, Hinali Patel, Ekramy M Elmorsy iD, Jessan A Jishu iD, Hani Aiash, Manal S Fawzy iD

Endocrinology, Diabetes & Metabolism · 2026-05 · 9 (3)

DOI: 10.1002/edm2.70239 ↗

Kurz gefasst

Kohortenstudie in der Zeitschrift Endocrinology, Diabetes & Metabolism, online erschienen am 18.05.2026. Verfasst von Eman A Toraih und 11 weiteren Autor:innen. Beteiligte Einrichtung: Genetics Unit, Department of Histology and Cell Biology, Suez Canal University Faculty of Medicine, Ismailia, Egypt. Hauptthemen laut MEDLINE: Hashimoto Disease, Selenium, Dietary Supplements. Die Arbeit nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Selenium supplementation has been suggested as a therapeutic option for Hashimoto's thyroiditis, but its effects on thyroid function and other patient‐related outcomes remain unclear.

Methods

This retrospective cohort study utilised a global federated health research network to compare patients with Hashimoto's thyroiditis who received selenium supplementation after diagnosis to those who did not. Propensity score matching was performed to balance baseline characteristics. Primary outcomes included longitudinal thyroid function measures, while secondary outcomes included development of autoimmune diseases, thyroid cancer, need for thyroidectomy and all‐cause mortality. All outcomes were followed for 5 years.

Results

After matching, 2347 patients were included in each cohort. Selenium supplementation was associated with persistently higher mean TSH, free T4 and TPOAb levels, as well as greater proportions of elevated TPOAb (> 35 IU/mL) at 3 years (6.9% vs. 5.0%, p = 0.01) and 5 years (7.9% vs. 5.3%, p < 0.01). The incidence of autoimmune disorders was higher in the selenium group (RR 1.33, 95% CI 1.14–1.56), particularly Sjögren's syndrome (RR 1.61, 95% CI 1.03–2.52) and psoriasis (RR 2.69, 95% CI 1.52–4.76). The rates of thyroid cancer and need for thyroidectomy were similar between groups. However, selenium use was associated with increased all‐cause mortality (RR 1.38, 95% CI 1.09–2.03).

Conclusion

Selenium supplementation in Hashimoto's thyroiditis was associated with worsened biochemical autoimmunity, increased autoimmune comorbidity and higher mortality. These findings should be interpreted cautiously given the absence of baseline selenium measurements, which limits assessment of deficiency status. Nevertheless, they highlight the need for further research to confirm these results.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hashimoto DiseaseSeleniumDietary SupplementsHumansFemaleRetrospective StudiesMaleMiddle AgedAdultTreatment Outcome

Stichwörter der Autor:innen

Hashimoto's thyroiditisTriNetXautoimmunepropensity score matchingselenium

Substanzen

Selenium

Autor:innen und Institutionen

  • Genetics Unit, Department of Histology and Cell Biology, Suez Canal University Faculty of Medicine, Ismailia, Egypt.
  • SUNY Upstate Medical University, Syracuse, New York, USA.
  • Tulane University School of Medicine, New Orleans, Louisiana, USA.
  • Department of Internal Medicine, University of California, Riverside, California, USA.
  • Department of Basic Sciences, Faculty of Physical Therapy, Horus University-Egypt, New Damietta, Egypt.
  • Department of Biological Sciences, Faculty of Science, New Mansoura University, New Mansoura City, Egypt.

ORCID-Profile: Eman A Toraih, Rami M Elshazli, Mohammad H Hussein, Ekramy M Elmorsy, Jessan A Jishu, Manal S Fawzy

Zitieren

APA

Toraih, E. A., Yaghi, S., Ardis, C., Tran, L., Abdelmaksoud, A., Elshazli, R. M., Hussein, M. H., Patel, H., Elmorsy, E. M., Jishu, J. A., Aiash, H., & Fawzy, M. S. (2026). Clinical Outcomes of Selenium Supplementation in Hashimoto's Thyroiditis Without Selenium Deficiency: A Large‐Scale Retrospective Cohort Study. Endocrinology, Diabetes & Metabolism, 9(3). https://doi.org/10.1002/edm2.70239

Vancouver

Toraih EA, Yaghi S, Ardis C, Tran L, Abdelmaksoud A, Elshazli RM, et al. Clinical Outcomes of Selenium Supplementation in Hashimoto's Thyroiditis Without Selenium Deficiency: A Large‐Scale Retrospective Cohort Study. Endocrinology, Diabetes & Metabolism. 2026;9(3). doi:10.1002/edm2.70239

BibTeX
@article{Toraih2026,
  author = {Toraih, Eman A and Yaghi, Sarah and Ardis, Claire and Tran, Lori and Abdelmaksoud, Ahmed and Elshazli, Rami M and Hussein, Mohammad H and Patel, Hinali and Elmorsy, Ekramy M and Jishu, Jessan A and Aiash, Hani and Fawzy, Manal S},
  title = {Clinical Outcomes of Selenium Supplementation in Hashimoto's Thyroiditis Without Selenium Deficiency: A Large‐Scale Retrospective Cohort Study},
  journal = {Endocrinology, Diabetes & Metabolism},
  year = {2026},
  volume = {9},
  number = {3},
  doi = {10.1002/edm2.70239}
}
Kostenlos starten →